abbott.mediaroom

Abbott's Cologuard Plus® receives CE Mark for colorectal cancer screening in Europe

Cologuard Plus is a noninvasive, stool-based DNA screening test designed to detect both colorectal cancer and advanced precancerous lesions In the pivotal BLUE-C study, Cologuard Plus ...
abbott.mediaroom

Abbott introduces Ensure® Max Protein 3-in-1 Muscle Support, bringing the benefits of a supplement stack into one scoop

New powder combines 30 grams of high‑quality protein to help build muscle tissue,† 5 grams of creatine monohydrate to support muscle recovery‡* and 3 grams of calcium ...
abbott.mediaroom

Abbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition

For the first time, U.S. CardioMEMS patients will be able to view pulmonary artery pressure (PAP) readings and receive personalized medication updates through the CardioGuide HF App Rising PAP can ...
abbott.mediaroom

Abbott launches SimpleScreen™ CRC blood test, joining Cologuard Plus® in its colorectal cancer screening portfolio

Only Abbott offers a complete screening solution combining end-to-end support with both stool- and blood-based colorectal cancer screening options, giving healthcare providers more ways to help ...
abbott.mediaroom

Abbott reaches agreement with Department of Justice to resolve claims relating to 2022 infant formula recall

ABBOTT PARK, Ill., Sept. 14, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) has reached an agreement to resolve the previously disclosed investigation and lawsuit brought by the United States Department of ...
abbott.mediaroom

Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of stroke

Amulet 360 helps seal the left atrial appendage (LAA) of a person's heart, reducing the need for blood-thinning medication Amulet 360 builds upon Abbott's first-generation LAA device with design ...
abbott.mediaroom

Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants

Agreements will resolve the Gill case and claims involving approximately 2,000 other individuals Abbott and the medical community stand by the safety of preterm infant formulas Regulators and medical ...
abbott.mediaroom

Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI

Multi-year collaboration combines ongoing glucose insights from Abbott's Lingo biowearable with Google Health's technology to create a more comprehensive view of personal health Partnership includes a ...
abbott.mediaroom

Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance

Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $101 million of ...
abbott.mediaroom

Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes

First-of-its-kind biowearables combine continuous glucose and ketone monitoring in a single sensor to support both daily diabetes management and help detect rising ketone levels that can lead to ...
abbott.mediaroom

Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026

Data highlight how screening and diagnostics enable earlier detection, more precise treatment decisions, and improved patient outcomes from risk to remission New MRD data from the PARTNER study ...
abbott.mediaroom

Abbott receives FDA clearance and CE Mark for next-generation Ultreon™ 3.0 AI-powered coronary imaging platform

Ultreon 3.0 is the first advanced optical coherence tomography (OCT) system in the U.S. and Europe that integrates high resolution coronary plaque images and AI-automated insights through the artery ...